WT1/HLA-A02-specific T cell engager therapy(Biocytogen Pharmaceuticals/CtM Biotech)

N/A

Report date: 2026/03/19 17:15:15

Base Information

Drug NameWT1/HLA-A02-specific T cell engager therapy(Biocytogen Pharmaceuticals/CtM Biotech)
Drug Alias NameMulti-Specific T Cell Engager Targeting WT1/HLA-A02(Biocytogen Pharmaceuticals/CtM Biotech)三特异性T细胞连接器靶向WT1/HLA-A02的T细胞连接器-WT1xCD3x4-1BB三抗
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9Anti-CD3Anti-Wilms' Tumour 1
TargetsWilms' Tumour 1T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCtM Biotech (Shanghai) Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCtM Biotech (Shanghai) Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A